Imricor Medical Systems (ASX:IMR) EBIT: A$-38.50 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IMR Imricor Medical Systems Inc ASX:IMR
45 GF Score
Price A$1.68
GF Value A$0.10
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Imricor Medical Systems EBIT?

Imricor Medical Systems ASX:IMR +0.60% 45 EBIT is A$-38.50 Mil as of Dec. 2025. GuruFocus rates ASX:IMR with a GF Score™ of 45/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Imricor Medical Systems's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-18.33 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-38.50 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Imricor Medical Systems's annualized ROC % for the quarter that ended in Dec. 2025 was -217.33%. Imricor Medical Systems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -984.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Imricor Medical Systems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -6.63%.

Imricor Medical Systems  (ASX:IMR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Imricor Medical Systems's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-37.632 * ( 1 - 0% )/( (7.399 + 27.232)/ 2 )
=-37.632/17.3155
=-217.33 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=85.349 - 0.622 - ( 77.328 - max(0, 3.067 - 80.476+77.328))
=7.399

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=68.864 - 3.185 - ( 61.374 - max(0, 26.143 - 64.59+61.374))
=27.232

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Imricor Medical Systems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.652/( ( (3.7 + max(0.523, 0)) + (3.225 + max(-4.772, 0)) )/ 2 )
=-36.652/( ( 4.223 + 3.225 )/ 2 )
=-36.652/3.724
=-984.21 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.392 + 1.875 + 0.881) - (0.622 + 0 + 2.003)
=0.523

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.363 + 1.649 + 1.204) - (3.185 + 0.051 + 4.752)
=-4.772

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Imricor Medical Systems's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-38.504/580.859
=-6.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imricor Medical Systems EBIT Related Terms

Imricor Medical Systems EBIT Historical Data

* Premium members only.

The historical data trend for Imricor Medical Systems's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imricor Medical Systems EBIT Chart

Imricor Medical Systems Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -27.43 -25.46 -33.73 -46.85 -38.10

Imricor Medical Systems Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.00 -10.32 -36.04 -20.18 -18.33

ASX:IMR vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Imricor Medical Systems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imricor Medical Systems EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Imricor Medical Systems's EV-to-EBIT falls into.


ASX:IMR
45GF Score
Imricor Medical Systems Inc ASX:IMR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imricor Medical Systems EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-38.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-38.50 Mil mean?
Imricor Medical Systems (ASX:IMR) has a EBIT of A$-38.50 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Imricor Medical Systems.
Is Imricor Medical Systems' EBIT too high?
Imricor Medical Systems' current EBIT is A$-38.50 Mil. Overall, Imricor Medical Systems has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' EBIT compare to ABT and SYK?
Imricor Medical Systems' EBIT of A$-38.50 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Imricor Medical Systems. Imricor Medical Systems's current EBIT is A$-38.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.68 — trading 1580% above its estimated fair value. The current EBIT is A$-38.50 Mil. Imricor Medical Systems' overall GF Score™ is 45/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current EBIT is A$-38.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued. The current stock price of A$1.68 is trading 1580% above its estimated GF Value™ of A$0.10. GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.

Key valuation signals for ASX:IMR:

  • EBIT: A$-38.50 Mil
  • GF Value™: A$0.10 vs. price of A$1.68 (1580% above fair value)
  • GF Score™: 45/100 with 10 warning signs

No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imricor Medical Systems Business Description

Address 400 Gateway Boulevard, Burnsville, MN, USA, 55337
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
45GF Score

Get the complete analysis for ASX:IMR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.68
Price
A$0.10
GF Value